Monday, November 28, 2016

BRIEF-Windtree Therapeutics says presented Aerosurf Phase 2A data

* Windtree Therapeutics' Aerosurf (lucinactant for

inhalation) phase 2A data presented at the 2016 International

Congress of Union of European Neonatal and Perinatal Societies

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)